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The IκB Kinase Inhibitor, NEMO-binding Domain Peptide, for Inhibition of Balloon 
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Abstract 
Objective - The activation of the nuclear factor (NF)-κB is a crucial step in the arterial wall’s 
response to injury. The identification and characterization of the NF-κB essential modulator 
(NEMO)-binding domain (NBD) peptide, that can block the activation of the IκB kinase 
(IKK) complex, have provided an opportunity to selectively abrogate the inflammation-
induced activation of NF-κB. The aim of the present study was to evaluate the effect of the 
NBD peptide on neointimal formation. 
Methods and Results - In the rat carotid artery balloon angioplasty model local treatment with 
the NBD peptide (300 µg/site) significantly reduced the number of proliferating cells at day 7 
(by 40%; P<0.01) and reduced injury-induced neointimal formation (by 50%; P<0.001) at day 
14. These effects were associated with a significant reduction of NF-κB activation and 
monocyte chemotactic protein-1 expression in the carotid arteries of rats treated with the 
peptide. In addition, the NBD peptide (0.01-1 µM) reduced rat SMC proliferation, migration, 
and invasion in vitro. Similar results were observed in apolipoproteinE
-/-
 mice in which the 
NBD peptide (150 µg/site) reduced wire-induced neointimal formation at day 28 (by 47%; 
P<0.01). 
Conclusions - The NBD peptide reduces neointimal formation and SMC 
proliferation/migration, both effects associated with the inhibition of NF-κB activation. 
 
Key Words: Angioplasty, NEMO binding domain peptide, NF-κB, Pharmacology, Vascular 
biology. 
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The transcriptional factor nuclear factor κB (NF-κB) plays a critical role in the 
pathophysiological processes leading to neointimal formation.
1
 Activated NF-κB is detected 
in human restenotic lesions, vascular smooth muscle cells (SMCs), monocytes, and 
endothelial cells.
2
 Activated NF-κB has also been found in balloon-injured rat carotid arteries 
and has been associated with neointimal formation and expression of NF-κB regulated genes 
such as vascular cell adhesion molecule-1 (VCAM-1), monocyte chemotactic protein-1 
(MCP-1) and tumor necrosis factor-α (TNF-α).
3-6
 Consistent with its role in vascular injury, 
blocking NF-κB activation via transfection of adenoviral IκB 
7
 or NF-κB “decoy”
 
oligodeoxynucleotides, attenuated neointimal
 
formation after balloon injury in animal 
models.
8
 Recently, the first clinical use of a NF-κB decoy at the site of coronary stenting for 
the prevention of restenosis has been described.
9
 
NF-κB activation influences SMC viability and migration/invasion by inducing genes with 
survival functions 
5,10,11
 and genes involved in matrix degradation.
12
 On the other hand, 
several inflammatory mediators involved in neointimal hyperplasia (e.g. TNF-α), are able to 
activate NF-κB in SMCs in vitro.
5
 These findings link the activation of NF-κB to neointimal 
formation and to the inflammatory response associated with injury-induced SMC 
proliferation/migration; thus validating NF-κB as a potential target for the control of 
neointimal hyperplasia. However, the indispensable role played by NF-κB in many biological 
processes has raised concern that a complete shutdown of this pathway would have significant 
detrimental effects on normal cellular function. Instead, drugs that selectively target only the 
inflammation-induced NF-κB activity would be of greater therapeutic value. 
A key step in NF-κB activation is the phosphorylation of IκB proteins by the IκB kinase 
(IKK) complex (IKKα, IKKβ, and NF-κB essential modulator or NEMO).
13
 NEMO regulates 
the IKK complex activity through its binding to the carboxyl-terminal region of the IKKα and 
IKKβ, termed NEMO-binding domain (NBD). In this regard, a cell-permeable NBD peptide 
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has been shown to block the association of NEMO with the IKK complex, inhibiting NF-κB 
activation and ameliorating inflammatory responses.
14
 The potential of this peptide as an anti-
inflammatory agent has been demonstrated in vivo in various animal models including 
phorbol ester-induced ear edema and zymosan-induced peritonitis,
14
 LPS-induced septic 
shock,
15
 mouse carrageenan-induced paw edema,
16
 and in a mouse model of experimental 
arthritis.
17
 Importantly the NBD peptide does not completely inhibit NF-κB activity, 
suggesting that selective disruption of the interaction of NEMO and IKKβ will most likely 
leave residual NF-κB activity that might be sufficient to maintain normal cellular processes.
14
 
Nevertheless, the effects of a highly selective pharmacological inhibition of the 
proinflammatory IKK activity have not yet been investigated in vascular injury. 
Therefore, the aim of the present study was to investigate the effect of the NBD peptide on 
neointimal formation in vivo using two well-known animal models of arterial injury: the rat 
carotid artery balloon angioplasty and the wire-induced carotid injury in apolipoprotein E-
deficient (apoE
-/-
) mice. In addition, the effects of the NBD peptide on SMC proliferation and 
migration in vitro were also examined. Our results support the selective targeting of IKK as a 
powerful approach in the control of neointimal formation. 
 
Methods 
Cell culture 
Primary aortic SMCs were isolated from the thoracic aorta of male Wistar rats as previously 
described 
18
 and grown in Dulbecco’s modified Eagle medium (DMEM; Cambrex Bio 
Sciences) supplemented with L-glutamine, 10% fetal bovine serum (FBS; Cambrex Bio 
Sciences), 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified incubator at 
37°C in 5% CO2. Before initiation of the assays, the SMCs were starved into DMEM 
supplemented with 0.1% FBS for 48 h. Studies were performed with cells at passages 3-6. 
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Cell proliferation study 
SMC proliferation was quantified by the total cell number as previously reported.
18
 Briefly, 
5x10
3
 cells were seeded onto 48-multiwell plates and allowed to adhere overnight. Starved 
cells were stimulated with TNF-α (5 ng/mL; R&D Systems), PDGF-BB (10 ng/mL; R&D 
Systems) or FGF-2 (10 ng/mL; R&D Systems) in the presence or absence of the NBD peptide 
(0.01-1 µM; Genosphere Biotech). After 72 hours, cells were fixed with methanol and stained 
with Diff-Quik. Proliferation was evaluated as cell duplication by counting the number of 
cells in ten random fields of each well at 200X magnification (TNF-α experiment) or 400X 
magnification (PDGF-BB and FGF-2 experiments) with the aid of a 21 mm
2
 ocular grid. 
Chemotactic migration and invasion 
The modified Boyden chamber (48-multiwell plates; Neuroprobe) was used for chemotaxis 
studies.
18,19
 Polyvinyl-pyrrolidone-free polycarbonate filters, 8 µm pore size, were coated 
with 100 µg/mL collagen type I and 10 µg/mL fibronectin. Biocoat Matrigel invasion 
chambers (24-multiwell plates with 8.0 µm pore size filter; Becton Dickinson) were used 
according to the manufacturer’s instructions for invasion studies. TNF-α (5 ng/mL), PDGF-
BB (10 ng/mL) or FGF-2 (10 ng/mL) were added to the lower wells, while starved cells 
(12x10
3
 for migration assay and 3x10
4
 for invasion assay) were seeded into the upper wells of 
the chamber, and incubated at 37°C. The NBD peptide (0.01-1 µM) was added to the cell 
suspension 60 min before seeding. After 4h for migration assay or 48h for invasion assay, the 
migrated cells were fixed and stained with haematoxylin. Cell migration was measured by 
microscopic evaluation of the number of cells moved across the filter, in ten random fields for 
the migration assay and in the entire filter for the invasion assay. 
Flow cytometry 
Apoptosis was quantified by flow cytometry, using a commercially available Annexin V- 
Alexa Fluor® 488 apoptosis detection kit following the manufacturer’s guidelines (Molecular 
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Probes
TM
). Starved SMCs were stimulated for 24h with TNF-α (5 ng/mL) then washed twice 
in PBS, trypsinized, and collected. To evaluate the effect of the NBD peptide, SMCs were 
pretreated for 1h with the peptide (1 µM) before the TNF-α stimulation. Cells were 
centrifuged, the supernatant discarded, and the cell pellet resuspended in the kit’s binding 
buffer. The cells were centrifuged again, the supernatant discarded, and the pellet resuspended 
in the kit’s buffer containing Alexa Fluor® 488 Annexin V solution and MitoTracker® Red 
dye. Samples were incubated in the dark for 10 minutes and analyzed using an Epics XL flow 
cytometer (Beckman Coulter) equipped with a 488-nm Argon laser. Apoptotic cells showed 
green fluorescence with decreased red fluorescence and live cells showed very little green 
fluorescence and bright red fluorescence. Isotype-matched antibodies were used as a negative 
control. 
Gelatin zymography 
Cells were cultured in 96-well culture plates in 10% FBS medium until 90% confluence was 
achieved. Starved cells were stimulated with TNF-α (5 ng/mL) in the presence or absence of 
the NBD peptide (1 µM). After 24h the media were collected, clarified by centrifugation and 
subjected to electrophoresis in 8% SDS-PAGE containing 1 mg/mL gelatin under non-
denaturing conditions. After electrophoresis the gels were washed with 2.5% Triton X-100 to 
remove SDS and incubated for 24 h at 37°C in 50 mM Tris buffer containing 200 mM NaCl 
and 20 mM CaCl2, pH 7.4. The gels were stained with 0.5% Coomassie brilliant blue R-250 
in 10% acetic acid and 45% methanol and destained with 10% acetic acid and 45% methanol. 
Bands of gelatinase activity appeared as transparent areas against a blue background. 
Gelatinase activity was then evaluated by quantitative densitometry. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Cells were used after the induction of quiescence in 24-well plastic culture plates at a density 
of 2×10
4
 cells/well. The cells were stimulated with TNF-α (5 ng/mL) in the presence or 
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absence of the NBD peptide (0.01-1 µM). After 24 hours media were collected, centrifuged at 
2000xg for 15 min at 4°C and supernatants were used for ELISA to detect MCP-1 
(OptEIA
TM
, Biosciences). 
Cytosolic and nuclear extracts 
Cells (1×10
5
) suspended in 10% FBS medium were seeded in 6-multiwell plates and allowed 
to adhere overnight. Cells
 
were kept in starving conditions for 48 h. The medium was then 
removed and replaced with fresh medium containing TNF-α (5 ng/mL) or PDGF-BB (10 
ng/mL) in the presence or absence of the NBD peptide (0.01-1 µM) or the mut-NBD peptide 
(1 µM). The NBD peptides used in this study were described previously.
16
 
The cell pellet was resuspended in 100 µL of ice-cold hypotonic lysis buffer (10 mM Hepes, 
10 mM KCl, 0.5 mM phenylmethylsulphonyfluoride, 1.5 µg/mL soybean trypsin inhibitor, 7 
µg/mL pepstatinA, 5 µg/mL leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and 
incubated on ice for 15 min. The cells were lysed by rapid passage through a syringe needle 
five times and centrifuged for 10 min at 13.000×g. The supernatant containing the cytosolic 
fraction was removed and stored at -80°C. The nuclear pellet was resuspended in 30 µL of 
high salt extraction buffer (20 mM Hepes pH 7.9, 10 mM NaCl, 0.2 mM EDTA, 25% v/v 
glycerol, 0.5 mM phenylmethylsulphonyfluoride, 1.5 µg/mL soybean trypsin inhibitor, 7 
µg/mL pepstatin A, 5 µg/mL leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and 
incubated at 4°C for 30 min with constant agitation. The nuclear extract was then centrifuged 
for 10 min at 6000×g with the supernatant aliquoted and stored at -80°C. Protein 
concentration was determined by the Bio-Rad protein assay kit (Bio-Rad). 
Western blot analysis 
Immunoblotting analysis of phospho-IκBα (Ser32/36) was performed on cytosolic extracts. 
The samples were mixed with gel loading buffer (50 mM Tris, 10% SDS, 10% glycerol, 10% 
2-mercaptoethanol, 2 mg/mL of bromophenol) in a ratio of 1:1, boiled for 3 min and 
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centrifuged at 1000×g for 5 min. An equivalent protein amount (30 µg) of each sample was 
electrophoresed in a 10% discontinuous polyacrylamide gel. The proteins were transferred 
onto nitro-cellulose membranes, according to the manufacturer’s instructions (Bio-Rad). The 
membranes were saturated by incubation for 2 h with 10% milk buffer and then incubated 
with the primary antibody (mouse anti-phospho-IκBα, 1:1000; Cell Signaling) at 4°C 
overnight. The membranes were washed three times with 0.01% Tween20 in PBS and then 
incubated with anti-rabbit or anti-mouse immunoglobulins coupled to peroxidase (1:1000; 
DAKO). The immunocomplexes were visualized using the ECL chemiluminescence method. 
Electrophoretic mobility shift assay (EMSA) 
Double stranded NF-κB consensus oligonucleotide probe (5’ AGC TTC AGA GGG GAC 
TTT CCG AGA GG 3’) was end-labelled with [
32
P]γ-ATP. Nuclear extracts (10 µg protein 
from each sample) were incubated for 20 min with radiolabelled oligonucleotides (2.5-
5.0x10
4
 cpm) in 20 µL reaction buffer containing 2 µg poly dI-dC, 10 mM Tris-HCl (pH 7.5), 
100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 µg/µL bovine serum albumin, 10% (v/v) 
glycerol. Nuclear protein-oligonucleotide complexes were resolved by electrophoresis on a 
5% non-denaturing polyacrylamide gel in 0.5 x Tris-borate/EDTA at 150 V for 2 h at 4°C. 
The gels were dried and autoradiographed with intensifying screen at -80°C for 24 hours. 
Animals 
Male Wistar rats (Harlan Laboratories) weighing 250 g and 8-week-old female apoE
-/-
 mice 
(Charles River) were used. Animals were housed at the Department of Experimental 
Pharmacology, University of Naples Federico II. All procedures were performed according to 
Italian ministerial authorization (DL 116/92) and European regulations on the protection of 
animals used for experimental and other scientific purposes. 
Rat carotid balloon angioplasty 
Rats were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) (Gellini 
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International) and xylazine (5 mg/kg) (Sigma). Endothelial denudation of the left carotid 
artery was performed with a balloon embolectomy catheter (2F, Fogarty, Edwards 
Lifesciences) according to the procedure validated in our laboratories.
19,20
 Immediately after 
endothelial denudation, 300 µg of the NBD peptide or 300 µg of the mut-NBD peptide in 100 
µL of pluronic gel (pH 7.2) was applied to the adventitia.
21,22
 The control group received 
pluronic gel only. Some animals were subjected to anesthesia and surgical procedure without 
balloon injury (sham-operated group). Rats were euthanized 7 and 14 days after angioplasty. 
Carotid arteries were collected and processed as described below. 
Atherogenic murine model of vascular injury 
ApoE
-/-
 mice were fed an atherogenic diet (21% fat, 0.15% cholesterol, 19.5% casein, wt/wt; 
TD88137, Mucedola) from 1 week before until 4 weeks after carotid injury performed as 
described previously,
19
 with minor modification. Briefly, mice were anaesthetized as 
described above, and endothelial injury of the left common carotid artery was performed with 
a 0.35 mm diameter flexible nylon wire introduced through the left external carotid artery and 
advanced to the aortic arch. The endothelium was damaged by passing the wire through the 
lumen of the artery three times. Immediately after endothelial denudation, 150 µg of the NBD 
peptide or 150 µg of the mut-NBD peptide in 50 µL of pluronic gel was applied to the 
adventitia. Carotid arteries were collected 28 days after wire injury and processed as 
described below. 
Evaluation of neointimal formation 
Carotid arteries were fixed by perfusion with phosphate-buffered saline (PBS; pH 7.2) 
followed by PBS containing 4% formaldehyde through a cannula placed in the left ventricle. 
Paraffin-embedded sections were cut (6 µm thick) from the approximate middle portion of the 
artery and stained with haematoxylin and eosin to demarcate cell types. Ten sections from 
each carotid artery were reviewed and scored under blind conditions. The cross-sectional 
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areas of tunica media and neointima were determined by a computerized analysis system 
(LAS, Leica). 
Proliferating Cell Nuclear Antigen Analysis 
Proliferating cell nuclear antigen (PCNA) analysis was used to quantify the proliferative 
activity of cells at the balloon injury sites, and was performed using monoclonal mouse anti-
PCNA antibody (1:250, PC10, Sigma) and biotinylated anti-mouse secondary antibody 
(1:400, DakoCytomation). Slides were treated with streptavidin-HRP (DakoCytomation) and 
exposed to diaminobenzidine chromogen (DakoCytomation) with hematoxylin counterstain. 
Six sections from each carotid artery and 10 fields per section were reviewed and scored 
under blind conditions. Data are represented as percentage of cells positive for PCNA 7 days 
after angioplasty. 
Immunohistochemical localization of the NBD peptide 
Localization of the biotinylated (bio)-NBD peptide in rat carotid arteries was performed by 
immunofluorescence in order to determine the temporal and spatial distribution of the peptide 
delivered to the adventitia. Briefly, 300 µg of the bio-NBD peptide (Genosphere Biotech, 
Paris, France) in 100 µl of pluronic gel were applied on the carotid artery immediately after 
the injury. Immunohistochemical analysis was performed on 5 µm frozen sections of rat 
carotid artery, 3, 7 and 14 days after injury. The biotinylated peptide was detected by texas 
red-conjugated streptavidin (1:100; DakoCytomation). For the identification of the SMC a 
monoclonal anti-α-SMA FITC (1:250, clone 1A4, Sigma) was used. DAPI was used to 
identify nuclei. 
Preparation of Total Extracts of rat carotid arteries 
All the extraction procedures were performed on ice with ice-cold reagents as described 
above. Briefly, liquid nitrogen frozen pooled carotid arteries (n=2) were crushed into powder 
and resuspended in an adequate volume of hypotonic lysis buffer and then centrifuged for 15 
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minutes at 6000xg with the supernatant being placed in aliquots, and stored at -80°C. Protein 
concentration was determined by the Bio-Rad protein assay kit. Total extracts were used to 
evaluate MCP-1 production and NF-κB activity by ELISA and EMSA respectively.  
Statistical analysis 
Results are expressed as mean ± SEM of n animals for in vivo experiments and mean ± SEM 
of multiple experiments for in vitro assays. Student’s t test was used to compare 2 groups or 
ANOVA (Two-Tail P value) was used with the Dunnett’s post hoc test for multiple groups 
using Graph Pad Instat 3 software (San Diego, CA). Non parametric Mann Whitney test was 
used for evaluation of neointimal formation. The level of statistical significance was 0.05 per 
test. 
 
Results 
Effect of the NBD peptide on NF-κB activation in SMCs 
Thirty minutes of stimulation with TNF-α (5 ng/mL) caused a significant IκBα 
phosphorylation at Ser32 (Figure 1A). Consistent with its mechanism of action, treatment 
with the NBD peptide reduced the phosphorylation of IκBα in a concentration-dependent 
manner. Treatment with the mut-NBD peptide (1 µM) did not affect IκBα phosphorylation 
(Figure 1A). To further confirm the inhibitory effect of the NBD peptide on NF-κB activation, 
we examined the NF-κB/DNA binding 4h after TNF-α stimulation. As shown in Figure 1B, 
the NBD peptide (0.01-1 µM) inhibited TNF-α-induced NF-κB activation. The relative 
densitometric analysis showed a concentration-dependent inhibition, significant at all 
concentrations studied (Figure 1B). The NBD peptide alone (1 µM) did not affect NF-κB 
basal activity (Figure 1B). The mut-NBD peptide (1 µM) showed no effect on TNF-α-induced 
NF-κB activation (data not shown). The NBD peptide (1 µM) inhibited PDGF-BB (10 
ng/mL)-induced NF-κB activation (data not shown). 
ATVB/2010/215467 (R1) 
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Effect of the NBD peptide on SMC proliferation and apoptosis 
Initiation and maintenance of SMC proliferation is a critical event in the pathogenesis of 
neointimal formation. As shown in Figure 2A, the NBD peptide (0.01-1 µM) significantly 
inhibited TNF-α-induced SMC proliferation by 15% (P<0.05, n=3), 20% (P<0.001, n=3), 
and 30% (P<0.001, n=3) respectively. This effect of the NBD peptide was not due to 
induction of cell apoptosis as demonstrated by flow cytometry analysis of Annexin V-labelled 
cells. The NBD peptide (1 µM) neither alone nor in presence of TNF-α (5 ng/mL) stimulated 
cell apoptosis (Figure 2B). Similarly, the NBD peptide (1 µM) significantly inhibited PDGF-
BB (10 ng/mL)-induced SMC proliferation by 27% (P<0.05, n=3) but was without effect 
when the stimulant was FGF-2 (10 ng/mL) (Supplemental Figure IA). 
Effect of the NBD peptide on SMC migration 
We also evaluated the effects of the NBD peptide on TNF-α-induced SMC chemotaxis. The 
NBD peptide significantly inhibited chemotactic migration by 15% (P<0.05, n=3) at 0.01 
µM, and about 20% (P<0.001, n=3) at both 0.1 µM and 1 µM (Figure 3A). The NBD peptide 
reduced PDGF-BB-, but not FGF-2-induced SMC migration (Supplemental Figure IB). 
Moreover, the NBD peptide (1 µM) significantly reduced SMC TNF-α-induced invasion (by 
70%, P<0.001, n=3) through the Matrigel
TM
 barrier which mimics the extracellular matrix 
(Figure 3B). 
Effect of the NBD peptide on MMP2 and MMP9 activity 
Subconfluent cultures of SMCs were exposed to TNF-α (5 ng/mL) for 24h in the presence or 
absence of the NBD peptide (1 µM) to assess gelatinase production. Gelatin zymography of 
control supernatants showed the constitutive release of the latent forms of MMP-2, visualized 
as a band at 72 and 68 kDa. TNF-α stimulated the release of MMP-2 and induced its 
activation as revealed by the appearance of the 62 kDa form (Figure 4A). The NBD peptide 
significantly (P<0.05) inhibited the latent form of MMP-2 without affecting the activated 
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form and slightly decreased, although not significantly, the TNF-α-induced MMP-9 
gelatinase active form production (92 kDa) (Figure 4A,B). 
Effect of the NBD peptide on MCP-1 production 
MCP-1 production by cultured rat SMCs was determined in cell supernatants by ELISA. As 
shown in Figure 4C, stimulation of SMCs with TNF-α (5 ng/mL) caused an increased release 
of MCP-1 compared to that observed in unstimulated cells. In the presence of the NBD 
peptide (0.01-1 µM) a concentration-related inhibition of MCP-1 production was observed. 
Interestingly, the NBD peptide, at higher concentrations totally abolished TNF-α-induced 
MCP-1 production. The NBD peptide alone (1 µM) did not affect basal MCP-1 production 
(Figure 4C). 
Effect of the NBD peptide on neointimal formation in rat injured carotid arteries 
Rats were treated with either the NBD peptide, the mut-NBD peptide (300 µg/site), or an 
equal volume of pluronic gel (100 µL, control group) immediately after balloon injury. A 
reduction of proliferating cells was demonstrated in the carotid arteries of the NBD peptide-
treated rats 7 days after injury (P<0.01, n=5) (Figure 5A). Moreover, the NBD peptide 
treatment caused a significant inhibition of neointimal formation by 54% (P<0.01, n=10) at 
day 14 compared with the control group (Figure 5B). The local application of the mut-NBD 
peptide (300 µg/site) did not affect neointimal formation (n=5; Figure 5B). In addition, the 
NBD peptide significantly (P<0.01) increased the lumen area and decreased neointima/media 
ratio (Supplemental Table I). 
Effect of the NBD peptide on NF-κB activation in rat injured carotid arteries 
To support the hypothesis that the reduction of neointimal thickness correlated with NF-κB 
inhibition, the NF-κB/DNA binding activity was evaluated on extracts from carotid arteries 
by EMSA. The NBD peptide, but not the mut-NBD peptide, significantly (n=3, P<0.001) 
reduced balloon-induced NF-κB activation in injured arteries 3 and 14 days after injury. A 
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low level of NF-κB/DNA binding activity was detected in total protein extracts from carotid 
arteries of sham-operated rats (Figure 5C,D). 
Effect of the NBD peptide on MCP-1 production in rat carotid arteries 
The NBD peptide was able to significantly inhibit MCP-1 protein production 7, and 14 days 
after injury, evaluated by ELISA as described above. In the contralateral carotid artery (data 
not shown) no significant changes were observed at any of the time points, compared with 
measurements in sham-operated animals (Figure 5E). 
Effect of the NBD peptide on neointimal formation in apoE
-/-
 mice 
Carotid endothelial denudation was performed in apoE
-/-
 mice fed an atherogenic diet. 
Twenty-eight days after injury, the neointimal area was reduced by 46% (P<0.01) in apoE
-/-
 
mice treated with the NBD peptide compared with mut-NBD-treated mice (Figure 5F). The 
NBD peptide significantly increased the lumen area (P<0.01) and decreased the 
neointima/media ratio (P<0.05) (Supplemental Table II). 
In vivo localization of the bio-NBD peptide 
No positive staining was found in noninjured arteries or pluronic gel-treated carotids 14 days 
after angioplasty. In contrast, the bio-NBD peptide was detectable in the adventitia and media 
of injured vessels 3 days following injury. The bio-NBD peptide was also detectable in the 
media and the neointima at days 7 and 14 (Figure 6). 
 
Discussion 
The results obtained in this study show that the local administration of the NBD peptide, a 
selective inhibitor of IKK activation, reduces neointimal formation in rodent models of 
vascular injury mainly by inhibiting SMC activation. 
Increased SMC proliferation and acquisition of a pro-inflammatory phenotype are central 
features associated with the development
 
of neointimal lesions.
23
 The NBD peptide showed 
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both in vivo and in vitro anti-proliferative activity. Treatment with the NBD peptide 
diminished the number of PCNA-positive proliferating cells in the rat vessel wall 7 days after 
balloon injury, concomitant with the beginning of neointimal formation. Furthermore, the 
NBD peptide inhibited in vitro TNF-α- and PDGF-BB-induced rat SMC proliferation and 
migration, effects associated with the inhibition of NF-κB activation. On the contrary, the 
NBD peptide showed no effect on FGF-2-induced SMC proliferation/migration. This 
discrepancy could be explained by the fact that FGF-2 induces IκB degradation and NF-κB 
activation through a pathway distinct from TNF-α,
24
 and that p38 and p42/p44 MAPKs are 
also involved in FGF-2-induced SMC activation.
25
 Interestingly, although the NBD peptide 
significantly reduced rat SMC invasion through the Matrigel barrier, it was able to inhibit 
only the latent form of MMP2 without significantly affecting the activated forms of both 
MMP2 and 9, which are known to be required for SMC proliferation and migration into the 
intimal area of vascular wall.
26,27
 These results suggest that other proteases may co-operate 
with gelatinases in the TNF-α-induced cell invasion process. 
Activated NF-κB mediates the expression of several pro-inflammatory genes in SMCs among 
which, MCP-1 has been demonstrated to play a pivotal role in SMC proliferation/migration 
18,28
 and neointimal formation in several animal models.
19,28
 Interestingly, treatment with the 
NBD peptide significantly inhibited MCP-1 production, both in vitro and in vivo. Moreover, 
the total inhibition of MCP-1 production and SMC proliferation observed at the highest 
concentration (1µM) suggests that NF-κB triggers the autocrine/paracrine loop mechanism 
involved in the amplification of the inflammatory vascular response. 
Recent findings support the concept of NF-κB as a regional regulator of SMC survival rather 
than a direct promoter of proliferation of these cells.
10
 In our experiments the highest 
concentration of the NBD peptide showed no effect on SMC apoptosis, either when used 
alone or with TNF-α. These results are in contrast with previous data obtained by Obara et 
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al.,
29
 showing increased apoptosis rate in TNF-α-stimulated SMCs overexpressing a truncated 
IκBα. Our results could be justified, at least in part, by the use of a selective inhibitor of the 
IKK complex formation. It is known that in physiological conditions, NF-κB is partially 
activated and involved in cell survival.
10
 The NBD peptide inhibits only the inflammatory-
induced NF-κB activation without modifying the amount constitutively activated.
14,30
 To 
confirm this point we observed that the use of the NBD peptide, at higher concentrations, did 
not reduce the basal level of MCP-1 production compared to resting cells; most likely 
reflecting the fact that the NBD peptide does not affect basal NF-κB activity. 
In the last ten years, NF-κB has been investigated as a novel therapeutic target to prevent 
restenosis. However, the potential for developing effective therapeutic strategies based on 
NF-κB blockade remains to be determined. Several studies have targeted NF-κB activation in 
the control of vascular injury,
8
 and a phase I/IIa open-label multi-center study to assess the 
inhibitory effects of an NF-κB ODN decoy on in-stent coronary restenosis (INDOR Study) 
has reported the clinical safety of such an approach in humans.
31
 
In contrast to other therapeutic principles, the inhibition of the NF-κB system represents a 
broad-spectrum, multipurpose-weapon that can interfere with several fundamental 
pathophysiological mechanisms in the development of neointimal formation; targeting both 
proliferation and inflammation. In our study, the use of a peptide which selectively inhibits 
the IKK complex represents a novel and interesting approach. Compared with other NF-κB 
inhibitors tested to inhibit neointimal formation, the NBD peptide has the advantage of 
inhibiting the induction of NF-κB activation without inhibiting basal NF-κB activity that may 
be involved in fundamental cellular processes.
14,30
 Notably, the continuous administration of 
the peptide for >45 days did not lead to overt toxicity in mice.
17
 
Importantly, the Pluronic F-127 gel has been shown to be absorbed in vivo at 3 days. Such a 
short-term local administration of traditional NF-κB inhibitors (e.g. pyrrolidine 
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dithiocarbamate) has been shown to inhibit NF-κB activation in the injured vessels at day 3, 
without affecting intimal formation at day 14.
6
 Intriguingly, using the same delivery 
approach, we have clearly shown the presence of the biotinylated peptide in the rat media and 
neointima up to 14 days after injury. 
Importantly, the NBD peptide efficacy was also confirmed in the hyperlipidaemic mouse 
model: demonstrating the efficacy of the peptide under circumstances of increased vascular 
inflammation.
32
 
Both rodent models are not reliable experimental models of human angioplasty and as such, 
the present study has some limitations. It would be desirable to explore the efficacy and 
therapeutic potential of the NBD peptide in larger preclinical animal models. However, our 
results demonstrate the involvement of NF-κB as a regulator in the formation of neointima in 
mouse and rat vascular injury models and support the use of specific IKK inhibitors to reduce 
neointimal hyperplasia. 
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Legend to figures 
Figure 1. (A) Representative western blot showing the effect of the NBD peptide (0.01-1 µM) 
or the mut-NBD peptide (1 µM) on rat SMC IκBα phosphorylation induced by TNF-α (5 
ng/mL). (B) Representative EMSA and relative densitometric analysis showing the effect of 
the NBD peptide (0.01-1 µM) on TNF-α (5 ng/mL)-induced NF-κB activation in rat SMCs. 
Results are expressed as mean ± SEM of 3 separate experiments. ***P<0.001 vs TNF-α-
stimulated cells. 
Figure 2. (A) Upper panel: representative photomicrographs showing the inhibition of TNF-
α-induced proliferation by the NBD peptide. In the lower panel the graph shows the effect of 
the NBD peptide (0.01-1 µM) on SMC proliferation induced by TNF-α (5 ng/mL). Results are 
expressed as mean ± SEM of 4 experiments run in triplicate. *P<0.05; ***P<0.001 vs TNF-α-
stimulated cells. (B) Upper panel: representative histograms of apoptotic cells (black) 
stimulated for 24h with TNF-α (5 ng/mL), and the NBD peptide (1 µM) with or without TNF-
α. Positive control: 1mM H2O2 for 4h. Isotype-matched antibodies were used as negative 
control (white). In the lower panel the graph shows the effect of the NBD peptide (1 µM) with 
or without TNF-α on cell apoptosis. Mean ± SEM of 4 experiments. 
Figure 3. (A) Representative photomicrographs showing the inhibition of TNF-α-induced 
migration by the NBD peptide. In the lower panel the graph shows the effect of the NBD 
peptide (0.01-1 µM) on SMC migration induced by TNF-α (5 ng/mL). Results are expressed 
as mean ± SEM of 3 experiments run in triplicate. *P<0.05; ***P<0.001 vs TNF-α-stimulated 
cells. (B) Effect of the NBD peptide on SMC invasion through a matrigel
TM
 barrier induced 
by TNF-α. Results are expressed as mean ± SEM of 3 experiments run in triplicate. **P<0.01 
vs TNF-α-stimulated cells. 
Figure 4. (A) Representative gel zymography of conditioned medium from SMCs and 
relative densitometric analysis showing the effect of the NBD peptide on both MMP2 latent 
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(white columns) and activated (black columns) forms. Results are expressed as mean ± SEM 
of 4 experiments. *P<0.05 vs unstimulated cells; °P<0.05 vs TNF-α stimulated cells. 
(B) Representative gel zymography of conditioned medium from SMCs and relative 
densitometric analysis showing the effect of the NBD peptide on MMP9 activated form. 
Results are expressed as mean ± SEM of 4 experiments. **P<0.01 vs unstimulated cells. (C) 
Effect of the NBD peptide on MCP-1 production evaluated by ELISA on SMCs. Results are 
expressed as mean ± SEM of 3 experiments run in triplicate. **P<0.01 and *** P<0.001 vs 
TNF-α-stimulated cells. 
Figure 5. (A) Percentage of total medial and neointimal cells positive for PCNA 7 days after 
vascular injury. Results are expressed as mean ± SEM (n=5). **P<0.01 vs control group. (B) 
Representative microphotograph showing the effect of local administration of the NBD 
peptide (300 µg/site; n=10) or the mut- NBD peptide (300 µg/site; n=5) on the neointimal area 
in rat carotid artery, 14 days after injury. Control animals (n=10) received pluronic gel only as 
described in Methods. **P<0.001 vs control group. Scale bar = 200 µm. (C,D) Representative 
EMSA and relative densitometric analysis showing the effect of the NBD peptide (300 
µg/site; n=3) or the mut-NBD peptide (300 µg/site; n=3) on NF-κB activation in rat carotid 
arteries 3 (C) and 14 (D) days after angioplasty. Results are expressed as mean ± SEM of 3 
separate experiments. ***P<0.001 vs control group. (E) Effect of the NBD peptide (300 
µg/site) on MCP-1 expression in rat carotid arteries 7 and 14 days after balloon injury 
evaluated by ELISA. Results are expressed as mean ± SEM of MCP-1 levels normalized with 
protein concentrations, where n=3. **P<0.01 and ***P<0.001 vs control group; °°°P<0.001 
vs sham-operated animals. Sham (grey columns), Control (black columns), NBD (white 
columns). (F) Effect of local administration of the NBD peptide (150 µg/site; n=6) on 
neointimal area in apoE
-/-
 mouse carotid artery, 28 days after injury. **P<0.001 vs mut-NBD 
treated group (n=6). Scale bar = 100 µm. 
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Figure 6. Immunofluorescence visualization of α-SMA (green) and bio-NBD peptide (red) in 
rat carotid arteries 3, 7, and 14 days after balloon angioplasty. Dapi (blue) was used to locate 
nuclei. In the control group was used the pluronic gel only. 
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